SCHEMBL7290486

SCHEMBL7290486

COCOc1ccc(/C=C/C(=O)O)cc1OC

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.75
ALDH1A1 P00352 2/20 0.75
HPGD P15428 1/20 0.75
ALOX15 P16050 1/20 0.75
MAPK1 P28482 1/20 0.75
SMN1; SMN2 Q16637 1/20 0.75
HSD17B10 Q99714 1/20 0.75
SNCA P37840 2/20 0.71
CA12 O43570 1/20 0.62
CA1 P00915 1/20 0.62
CA2 P00918 1/20 0.62
CA3 P07451 1/20 0.62
PKM P14618 1/20 0.62
CSNK2A2 P19784 1/20 0.62
CA4 P22748 1/20 0.62
CA6 P23280 1/20 0.62
CA5A P35218 1/20 0.62
CA7 P43166 1/20 0.62
CSNK2B P67870 1/20 0.62
CSNK2A1 P68400 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7290494 1.00 KDM4E (0.75) KDM4EALDH1A1HPGDALOX15MAPK1
SCHEMBL4679399 0.94 KDM4E (0.75) KDM4EALDH1A1HPGDALOX15MAPK1
SCHEMBL4679405 0.94 KDM4E (0.75) KDM4EALDH1A1HPGDALOX15MAPK1
SCHEMBL18300366 0.94 KDM4E (0.65) KDM4EALDH1A1HPGDALOX15MAPK1
SCHEMBL18300365 0.94 KDM4E (0.65) KDM4EALDH1A1HPGDALOX15MAPK1
SCHEMBL9330299 0.91 KDM4E (0.61) KDM4EALDH1A1HPGDALOX15MAPK1
SCHEMBL9330303 0.91 KDM4E (0.61) KDM4EALDH1A1HPGDALOX15MAPK1
SCHEMBL5598665 0.90 NFKB1 (0.65) KDM4EALDH1A1HPGDALOX15MAPK1
SCHEMBL5598661 0.90 NFKB1 (0.65) KDM4EALDH1A1HPGDALOX15MAPK1
SCHEMBL5598621 0.89 FDPS (0.79) KDM4EALDH1A1HPGDALOX15MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200369605-A1 ONIUM SALT, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2020-11-26 US disclosed
US-5670498-A ADENOSINE ANTAGONISTS, TREATMENT OF PARKINSON*S DISEASE, ALZHEIMER*S DISEASE, OSTEOPOROSIS, DEPRESSION, ASTHMA KYOWA HAKKO KOGYO CO., LTD. (JP) 1997-09-23 US disclosed
US-5587378-A ADMINISTERING A SUBSTITUTED XANTHINE COMPOUND KYOWA HAKKO KOGYO CO., LTD. (JP) 1996-12-24 US disclosed
EP-0607607-B1 Xanthine derivatives KYOWA HAKKO KOGYO KK (JP) 1996-09-18 EP disclosed
US-5484920-A XANTHINE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 1996-01-16 US disclosed
EP-0607607-A1 Xanthine derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 1994-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369605-A1 ONIUM SALT, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS PAG1, SLC6A5, LBR KDM4E 3595/4885ALDH1A1 4139/4885HPGD 3903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.